QuidelOrtho names Erich Wolff as EVP of strategy & corporate development

SAN DIEGO - QuidelOrtho Corporation (NASDAQ:QDEL), a provider of in vitro diagnostics, has appointed Erich Wolff as Executive Vice President, Strategy & Corporate Development, the company announced Tuesday.

In his new role, Wolff will report to President and CEO Brian Blaser and will lead the company’s enterprise strategy, business development, government affairs and portfolio management functions.

Wolff brings over 20 years of leadership experience in strategy, mergers and acquisitions, and business development across healthcare sectors. He previously served as Buyouts Lead for MedTech and Life Sciences Tools & Diagnostics at Partners Group, a private equity firm managing $174 billion in assets.

Prior to that position, Wolff held senior leadership roles at BD and Medtronic. At Medtronic, he worked on revitalizing the company’s global diabetes business and oversaw corporate development for its neurosciences and diabetes units. During his time at BD, he contributed to the spinoff of embecta, the $1.5 billion acquisition of Parata Systems, and the divestiture of BD’s Surgical Instrumentation platform.

"Erich brings a rare combination of strategic vision, operational rigor and transaction expertise," said Blaser in the press release statement.

Wolff holds a Bachelor of Business Administration in Finance and Economics from the University of Wisconsin-Milwaukee.

QuidelOrtho develops and manufactures in vitro diagnostic solutions for immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company maintains a solid liquidity position with a current ratio of 1.12, though its stock has experienced a significant decline, down 42% year-to-date. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including QuidelOrtho.

In other recent news, QuidelOrtho Corporation reported impressive second-quarter 2025 earnings, with earnings per share reaching $0.12, significantly surpassing the forecast of $0.0015. The company’s revenue for the quarter was $614 million, slightly above expectations, highlighting strong financial performance. Despite these results, Raymond James lowered its price target for QuidelOrtho to $55 from $60, citing prudent guidance, although they maintained an Outperform rating on the stock. The firm noted that QuidelOrtho’s revenues were generally in line with expectations, with notable outperformance in the Labs segment. Additionally, QuidelOrtho launched a Certified Analyzer Program aimed at increasing diagnostic testing access in underserved rural communities across the United States. This initiative focuses on providing certified VITROS analyzers to smaller healthcare facilities at reduced costs while ensuring quality standards. These developments reflect QuidelOrtho’s ongoing efforts to expand its market presence and maintain robust financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.